Corbus Pharmaceuticals (CRBP) Projected to Release Earnings on Wednesday

Corbus Pharmaceuticals (NASDAQ:CRBP) is anticipated to issue its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect the company to post earnings of ($1.2725) per share and revenue of $1.67 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Friday, November 13, 2026 at 12:30 PM ET.

Corbus Pharmaceuticals (NASDAQ:CRBP) last released its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported ($1.81) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.26) by ($0.55). On average, analysts expect Corbus Pharmaceuticals to post ($5.89) EPS for the current fiscal year and ($6.47) EPS for the next fiscal year.

Corbus Pharmaceuticals Stock Performance

Shares of CRBP stock opened at $3.87 on Wednesday. Corbus Pharmaceuticals has a 52-week low of $3.73 and a 52-week high of $12.88. The stock’s 50-day moving average price is $6.91 and its 200 day moving average price is $8.56.

Wall Street Analyst Weigh In

A number of research firms have weighed in on CRBP. HC Wainwright reaffirmed a “buy” rating and set a $35.00 price objective on shares of Corbus Pharmaceuticals in a research report on Monday, September 14th. Oppenheimer dropped their target price on Corbus Pharmaceuticals from $52.00 to $48.00 and set an “outperform” rating on the stock in a report on Friday, August 7th. Wall Street Zen cut Corbus Pharmaceuticals from a “sell” rating to a “strong sell” rating in a research note on Saturday, August 8th. Mizuho set a $33.00 price target on Corbus Pharmaceuticals in a research note on Thursday, August 13th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Corbus Pharmaceuticals in a report on Thursday, October 15th. Seven analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Corbus Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $39.57.

Insider Activity at Corbus Pharmaceuticals

In related news, CEO Yuval Cohen sold 17,000 shares of the business’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $10.08, for a total transaction of $171,360.00. Following the sale, the chief executive officer owned 157,316 shares of the company’s stock, valued at approximately $1,585,745.28. The trade was a 9.75% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Sean F. Moran sold 12,000 shares of the company’s stock in a transaction dated Friday, August 7th. The stock was sold at an average price of $10.08, for a total transaction of $120,960.00. Following the transaction, the chief financial officer owned 84,694 shares in the company, valued at $853,715.52. The trade was a 12.41% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 456,000 shares of company stock worth $2,050,500. 3.50% of the stock is owned by company insiders.

About Corbus Pharmaceuticals

Corbus Pharmaceuticals Holdings, Inc is a biopharmaceutical company focused on developing medicines for serious diseases in oncology and immunology. The company’s research is centered on therapies designed to modulate immune-cell activity and target biological pathways involved in cancer and inflammatory disease.

Corbus’ oncology pipeline has included soquelitinib, formerly known as CPI-818, an oral, selective inhibitor of interleukin-2-inducible T-cell kinase (ITK) being evaluated for its potential to treat T-cell lymphomas and other cancers.